Clinical trials: Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
This is single-arm, observational, academic, investigator-driven study investigating the efficacy of liver transplantation after successful and sustained downstaging/tumor control of liver-limited unresectable intrahepatic…
- Trial name
- iCOLA (NCT06862934)
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Intrahepatic Cholangiocarcinoma by AJCC V8 Stage
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma
This study is designed to observe and evaluate the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of Gemcitabine PLUS Cisplatin in patients who were…
- Trial name
- NCT04413734
- Testing
- Combination therapy, Mono-chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent.
- Conditions
- Carcinoma of Intrahepatic and Extra-hepatic Biliary System, Carcinoma of Gallbladder, Bile Duct Cancer, Cholangiocarcinoma
- Trial name
- NCT02375880
- Testing
- DKN-01, gemcitabine, cisplatin
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Leap Therapeutics, Inc.
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
This phase I trial studies the side effects of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel in combination with gemcitabine and cisplatin in treating patients with biliary tract cancer that has…
- Conditions
- Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
- Trial name
- NCT05285358
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the…
- Conditions
- Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04491942
- Testing
- Cisplatin, Elimusertib, Gemcitabine Hydrochloride
- Where
- 8 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocarcinoma, Liver Tumor
Treat Primary and Metastatic Liver Tumors
The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature.
- Conditions
- Intrahepatic Cholangiocarcinoma, Liver Tumor, Metastatic Cancer, Metastatic Liver Cancer
- Trial name
- NCT05240040
- Sponsor
- Methodist Health System
Advanced Intrahepatic Cholangiocarcinoma
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
- Trial name
- NCT06858735
- Testing
- Durvalumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocarcinoma (ICC) that may be technically resectable but is difficult to remove directly by surgery.
- Trial name
- H-FROG (NCT07847710)
- Testing
- Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin
- Where
- China
- Volunteers
- 81 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
This phase II trial studies how well trifluridine/tipiracil and irinotecan work in treating patients with biliary tract cancer that has spread to other places in the body (advanced) and has not responded to treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma, Refractory Gallbladder Carcinoma
- Trial name
- NCT04072445
- Testing
- Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Intrahepatic Cholangiocarcinoma, Machine Learning
A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma
The object of this study is to develop a model for prediction of lymph node metastasis among intrahepatic cholangiocarcinoma (ICC) patients.
- Trial name
- NCT06290739
- Testing
- lymph nodes dissection
- Where
- China
- Volunteers
- 483 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study
Second-line regimen with or without consolidative radiotherapy in patients with oligometastatic/locally advanced unresectable intrahepatic cholangiocarcinoma: an open-label, randomised, controlled study.
- Trial name
- SED-RO-ICC (NCT06946849)
- Testing
- radiotherapy, FOLFIRI or FOLFOX or Regorafenib
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
The purpose of the study is to observe the effect of PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection.
- Trial name
- NCT04782804
- Testing
- Capecitabine, PD-1 Antibody（Tislelizumab）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Advanced Intrahepatic Cholangiocarcinoma
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
The main purpose of this study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody and standard chemotherapy regimen for the treatment of…
- Trial name
- NCT06956716
- Testing
- individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + cisplatin (GP), Sintilimab injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Intrahepatic Cholangiocarcinoma
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
The median survival of intrahepatic cholangiocarcinoma remains less than one year, highlighting the need for new treatments. Hepatic arterial infusion chemotherapy (HAIC), especially with fluoropyrimidine-based regimens, has…
- Trial name
- NCT06370663
- Testing
- Radiotherapy, HAIC (GEMOX), Chemotherapy
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Shandong Cancer Hospital and Institute
Intrahepatic Cholangiocarcinoma
Next Generation Sequencing in Intrahepatic Cholangiocarcinoma
The aim of the present study is to perform a comprehensive molecular characterization of intrahepatic cholangiocarcinoma (ICC) in patients exposed to well-known or putative risk factors (such as asbestos) for this malignancy, in…
- Trial name
- EtherBil (NCT02184871)
- Testing
- exposure to different risk factors and molecular assessment
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Bologna
Intrahepatic Cholangiocarcinoma
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers
- Trial name
- NCT05930119
- Testing
- HMPL-453, Rabeprazole
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
This phase II trial assesses the feasibility (including both safety and tolerability) of conducting Next Generation Sequencing and administering targeted therapy (infigratinib) in the preoperative setting for patients with…
- Conditions
- Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT05514912
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Infigratinib Phosphate
- Sponsor
- Emory University
Cholestasis, Progressive Familial Intrahepatic 3
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Cholangiocarcinoma (CCK) is a rare tumor (2000 new cases/year in France) with very poor prognosis (overall survival < 3% at 5 years).
- Trial name
- CHOLANGIOSIR (NCT01383746)
- Testing
- Yttrium microsphere injection
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver and Intrahepatic Bile Duct Carcinoma
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care.
- Trial name
- NCT04785534
- Testing
- Clinical Evaluation, Laboratory Biomarker Analysis, Liver Ultrasonographic Elastography
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center